Research Article

Molecular Characterization of Clinical Isolates to Study *rpoB* Gene in *Mycobacterium tuberculosis* Complex

Shilpa Rana[1], Yusra Ahmad[1], Narotam Sharma[2*], Vijay Kumar[2] and Satish Chandra Nautiyal[2]

[1]*Faculty of Pharmacy, Uttarakhand Technical University, Suddhowala, Dehradun, Uttarakhand, India*

[2]*Central Molecular Research Laboratory, Department of Biochemistry, Shri Guru Ram Rai Institute of Medical and Health Sciences, Shri Guru Ram Rai University, Dehradun, Uttarakhand, India*

*Corresponding author: Narotam Sharma, Central Molecular Research Laboratory, Department of Biochemistry, Shri Guru Ram Rai Institute of Medical and Health Sciences, Shri Guru Ram Rai University, Dehradun, Uttarakhand, India, Tel: +919557650069; E-mail: sharmanarotam5@gmail.com

Abstract

One of the major health problems that can be seen around the world is Anti-microbial resistance and the main cause behind it, is easy availability and higher consumption of medicines. Rifampicin Resistance Tuberculosis (RRTB) occur when *rpo*B (RNA polymerase) gene in *Mycobacterium tuberculosis* (MTB) gets mutated and this *rpo*B gene encodes for beta-subunit of RNA polymerase. Clinical specimens including pulmonary and extra-pulmonary secretion were collected from patients and detected for Tuberculosis (TB) positive cases by targeting *mpb*64 (Mannose-Binding Protein) gene at 240 base pair. TB positive samples were taken to pre-amplification area for master-mix preparation for Polymerase Chain Reaction (PCR) by targeting specific gene (*rpo*B) by using forward (5'-CCGCGATCAAGGAGTTCTTC-3') and reverse primer (3'-ACACGATCTCGTCGCTAACC-5'). Samples were then taken to thermal cycler PCR for amplification of *rpo*B gene and then amplicons were taken for electrophoresis following the analyzing of amplicons in Electronic UV trans-illuminator system, in which *rpo*B gene was targeted at 315 base pair to determine if sample is positive for Rifampicin resistance.

Keywords: PCR; MTB; *mpb*64 gene; *rpo*B gene; Rifampicin

Introduction

Antimicrobial resistance has become one of the major health problems, especially in developing countries. The easy availability and higher consumption of medicines lead to the emergence of drug resistance [1]. India has shown high burden of infectious diseases in the world and the recent report has shown inappropriate and irrational use of antimicrobial agents against these diseases. The report has also shown that a large population in India suffers from inadequacy of finance, due to which favourable condition for drug resistance occurs [2]. In India, a recent study was conducted and highlighted the importance of rationalizing the use of antibiotic in order to limit antibiotic resistance [3]. Antibiotics cause cell retardation and cell-death by targeting and inhibiting essential cellular processes [4]. If bacteria are exposed to drugs below the level required to kill bacteria in a population (MBC or Minimum Bactericidal Concentration) they can mutate and resist antibiotic treatment [5]. Mechanism involved in minimizing the effect of antibiotic by bacteria, is by acquiring or increasing expression of drug efflux pumps. These pumps are responsible for expelling drug from cytoplasm and their ability to access to their target [6]. Mutation is responsible for causing extensive changes in transcriptone and proteome of the bacterium and alters the several proteins responsible for impacting resistance [7]. As a result these mutations promote further evolution of bacteria in a multi-drug environment, in a drug-specific manner. Thus they both provide resistance and spur further development of resistance [8]. The two parameters involved in evolution of resistance are - Resistance variability and Dose sensitivity [9]. In 1882 Robert Koch, the German microbiologist discovered that TB is caused by MTB, which is rod-shaped and is responsible for infecting one-third of the total world's population and death of the people [10]. There is an internationally recognized strategy known as DOTS (Direct Observation Treatment-short course) for delivering the basics TB case – finding and curing it. It is a management strategy for public health system that include political commitment, case-detection with quality-assured bacteriology, chemotherapy for short period, ensuring patients' adherence to treatment, adequate supply of drug and sound reporting and recording system [11]. Tuberculosis is caused by members of MTB – *M. bovis*, *M. microti* and *M. africanum* [12]. Drug resistant tuberculosis is defined as a case in which Tuberculosis excrete bacilli, resistant to one or more anti-tubercular drug [13]. There are generally three types of drug resistance – RRTB (Rifampicin Resistant TB), which occurs when *rpo*B gene in MTB gets mutated. This *rpo*B gene is responsible for encoding the β- sub unit of RNA polymerase [14]. MDR TB (Multi Drug Resistance TB, is resistant to Isoniazid and Rifampicin that are most effective first line TB drug [15]. XDR TB (Extensive Drug Resistance) is defined as the tuberculosis, which is resistant to Isoniazid+Rifampicin+at least 1 fluroquinolones+any of 2nd line injectable drugs-Kanamycin, Amikacin or Capreomycin [16]. Rifampicin is the first line drug used in treatment of Tuberculosis and its resistance is known as RRTB and by binding to beta-subunit of Mycobacterium tuberculosis, it inhibits Mycobacterial dependent RNA polymerase. *rpo*B gene is responsible for coding of beta subunit of RNA polymerase. Resistance to Rifampicin is indicated by mutation in *rpo*B gene [17]. Although acid fast bacilli (AFB) microscopy is most popular method for TB diagnosis but it has low sensitivity and is very slow method. In modern times Nucleic Acid Amplification (NAA) technology is being used due to their rapidity and sensitivity [18].

Materials and Methodology

The experiment was carried out at Central Molecular Research Laboratory, Department of Biochemistry, Shri Guru Ram Rai Institute of Medical and Health Sciences (SGRRIM&HS), Patel Nagar, Dehradun, Uttarakhand. Patients, who met the criteria of being TB positive cases, were recruited for the drug resistance study. Clinical specimens which includes Pulmonary such as Sputum, Pleural fluid, Bronchiolar alveolar lavage, bronchial secretions and extra pulmonary specimens such as Pus, Urine, Semen, Tissue, Endometrial blood, Cerebrospinal Fluid were considered for the study. Specimens were collected from patients attending Out Patient Department (OPDs) and In Patient Departments

(IPDs) of Shri Mahant Indresh Hospital, Dehradun, (Uttarakhand) India. Collected samples were taken for further testing in areas:

Bio-safety cabinet: After collecting the sample, centrifugation process was done for isolating the DNA and the isolation was done by silica column method.

Pre-amplification area: This area was used for master mix preparation for PCR by targeting the specific gene (*mpb*64 and *rpo*B at 240 and 315 base pair respectively).

Amplification area: In this area the amplification or multiplication of targeted gene was done by PCR.

Post amplification area: After amplification the product was tested or analysed by using electrophoresis unit.

Results

The present study was undertaken to detect mycobacterial infection in pulmonary and extra- pulmonary samples collected from patients. We used PCR as a tool for detecting mycobacterial *mpb*64 gene and *rpo*B gene resistance in both pulmonary and extra-pulmonary samples collected from suspected TB patient. 70 samples were taken from the different Departments in Shri Mahant Indiresh Hospital and processed in Central Molecular Research Laboratory, Department of Biochemistry, Shri Guru Ram Rai Institutes of Medical and Health Sciences, Patel Nagar, Dehradun, Uttarakhand, India. On the basis of presence of mycobacterium, 2 samples were found positive in the process of AFB staining while 9 samples were found positive in the process of PCR for *mpb*64 gene (TB), from which 5 samples came positive for *rpo*B gene resistance.

Positivity rate for pulmonary and extra-pulmonary cases

Grouping the samples on the basis of site of infection, it can be divided into 2 sites, named as Pulmonary Site and Extra Pulmonary Site. Total clinical sample received were 70 and out these 60 i.e., 85.75% were from extra pulmonary site, while 10 i.e., 14.28% were from pulmonary site. For gene *mpb*64, TB PCR that was found to be positive was 3 (5%) and negative cases were 57 (95%). In case of *rpo*B gene, no PCR was found to be positive, while 3 samples gave 100% negative PCR. The total cases for pulmonary infection were 10 (14.28%) out of 70 obtained clinical samples. In case of pulmonary samples, PCR positive for *mpb*64 gene was 60% while PCR negative for it was 40%. The PCR positive for *rpo*B gene were 5 (83.33%) that means there was resistance towards Rifampicin due to mutation in *rpo*B gene while PCR negative for it was 1 (16.66%). These whole data indicates that pulmonary samples were found to be more positive in case of *mpb*64 and also the resistivity by *rpo*B gene was high in it as compared to extra pulmonary samples (Table 1; Figure 1).

Figure 1: Percentage of positive cases for *rpo*B and *mpb*64 gene in pulmonary and extra pulmonary site.

Positivity and negativity rate for gender

Out of 70 received clinical samples; it was found that 30 samples were of females, which was 42.85% of total sample received and 40 were of males, which was 57.14%. In case of females, 3 samples (10%) were positive for *mpb*64 gene while 27 (90%) were negative for *mpb*64 gene but in case of *rpo*B gene 1 (33.33%) females showed positive response towards it, while 2 (66.66%) females showed negative response. In case of males, 6 (15%) were positive for *mpb*64 and 34 (85%) were negative towards it. While in case of *rpo*B gene, male 4 (66.66%) gave positive response by showing resistance to Rifampicin and 2 (33.33%) gave negative response by showing no mutation of *rpo*B gene. These whole data indicates that males are more prone to TB infection and also resistance towards Rifampicin in them is higher than females (Table 2; Figure 2).

Clinical specimen wise result interpretation

The data give information regarding specimen type being used and its response towards *mpb*64 gene and *rpo*B gene. Out of the 70 specimen received, maximum sample was of CSF that was 38.5%. The BAL sample showed the maximum positive response that is 85%, towards *mpb*64 gene indicating them as TB positive. In case of *rpo*B gene also, BAL sample showed maximum positive response that is 83.33% making it highly resistant against Rifampicin (Table 3; Figure 3).

Discussion

Global prevalence of infection due to MTB is 32% and enormity of the problem has increased with emergence of Rifampicin resistant strain of *Mycobacterium tuberculosis*. Patient at high risk of MDR TB are need to be screened, so for this purpose rapid, inexpensive and simple techniques are used. One technique can be mentioned to the rapid molecular methods, is based on amplification of DNA (NAA), which is used in order to follow the mutation in genes that are responsible for resistance to Rifampicin (*rpo*B gene) and other anti-tubercular drugs. After working on 70 samples during our lab scale work we concluded and analyzed the presence of mycobacterium in various samples of patients. Out of these 70 samples, 9 were found to be TB PCR positive for *mpb*64 gene and out of these 9 positive samples, 5 samples showed positive response for *rpo*B gene resistance, that means mutation in *rpo*B gene of *Mycobacterium tuberculosis* leading in resistance to Rifampicin drug. On the basis of gender we concluded that male were found to be more TB infected than female as indicated from table above. Percentage of males those were infected to mycobacterium was 15%, while females were 10%. In case of *rpo*B gene resistance also, males were higher in percentage and were found to be 66.66% and females were with percentage of 33.33%. In case of 'Site of Infection' by mycobacterium, extra-pulmonary site was found to be more infected than pulmonary site. In case of pulmonary TB infection, BAL sample showed most

Total cases	Positive cases of *mpb64* gene	Positive cases of *rpoB* gene
Extra-pulmonary site (60)	3(5%)	0(0%)
Pulmonary site (10)	6(60%)	5(83%)

Table 1: Positive cases for *mpb64* and *rpoB* gene in pulmonary and extra-pulmonary sites.

Gender	Total Cases	*mpb64* gene		*rpoB* gene	
		Positive	Negative	Positive	Negative
Female	30 (42.85%)	3 (10%)	27 (90%)	1 (33.33%)	2 (66.66%)
Male	40 (57.14%)	6 (15%)	34 (85%)	4 (66.66 %)	2 (33.33%)

Table 2: Positivity and negativity rate of *mpb64* and *rpoB* gene in males and females.

	Sample Types	Cases	*mpb64*		*rpoB* gene	
			Positive	Negative	Positive	Negative
1	Pus	5 (7.14%)	1 (20%)	4 (80%)	0	1 (20%)
2	Tissue	2 (2.85%)	0	2 (2.85%)	0	0
3	Endometrial blood	2 (2.85%)	0	2 (2.85%)	0	0
4	Bronchio-alveolar lavage	7 (10%)	6 (85%)	1 (14.28%)	5 (83.33%)	1 (16.66%)
5	Cerebrospinal fluid	27 (38.5%)	1 (3.7%)	26 (96.29%)	0	1 (3.7%)
6	Menstural blood	1 (1.42%)	0	1 (1.42%)	0	0
7	Pleural fluid	12 (17.14%)	1 (8.33%)	11 (91.66%)	0	1 (8.33%)
8	Ascitic fluid	7 (10%)	0	7 (10%)	0	0
9	Pericardial fluid	1 (1.42%)	0	1 (1.42%)	0	0
10	Sputum	2 (2.85%)	0	2 (2.85%)	0	0
11	Urine	2 (2.85%)	0	2 (2.85%)	0	0
12	Synovial fluid	1 (1.42%)	0	1 (1.42%)	0	0

**Table 3:** Percentage of available sample types and their response.

**Figure 2:** Percentage of positive cases for *mpb64* and *rpoB* gene in males and females.

**Figure 3:** Relationship between specimen types, *mpb64* and *rpoB* gene.

Figure 4: Gel picture representing positive and negative response for *rpoB* gene.

TB positive cases. 60% patients showed PCR positive for *mpb*64 gene and 83.33% showed resistance to *rpo*B gene. While in case of extra pulmonary infection, positive response given by *mpb*64 gene was only 5% and *rpo*B gene gave no response. By analyzing the result of specimen being used and its response towards *mpb*64 gene and *rpo*B gene, we concluded that BAL sample gave 85% positive response for *mpb*64 and 83.33% gave positive response for *rpo*B gene. Second highest positive response for *mpb*64 was given by Pus sample but it gave no positive response towards *rpo*B gene (Figure 4).

Conclusion

Resistance towards any anti-tubercular drug, act as an obstacle in the treatment of tuberculosis. The cause for drug resistance of Rifampicin could be patient's incompliance with their prescription as well as easy availability of drug (Rifampicin) at the drug counter for nose and throat infection. Carelessness in the diagnosis of TB may lead to drug resistance, which can affect the duration of TB treatment. *mpb*64 gene is not sufficient for the diagnosis of drug resistance in TB, so for this purpose *rpo*B gene (responsible for drug resistance) is targeted.

Acknowledgments

References

1. Levy SB, Marshall B (2004) Antibacterial resistance worldwide: Causes, challenges and responses. Nature Med 10: S122.

2. Wirsing RL, Logan MH, Micozzi MS, Nyamwaya DO, Pearce TO, et al. (1985) The health of traditional societies and the effects of acculturation [and comments and replies]. Curr Anthropol 26: 303-322.

3. O'brien DJ, Gould IM (2013) Maximizing the impact of antimicrobial stewardship: the role of diagnostics, national and international efforts. Current Opinion in Infectious Diseases 26: 352-358.

4. Zhang H, Burrows F (2004) Targeting multiple signal transduction pathways through inhibition of Hsp90. J Mol Med 82: 488-499.

5. Coates A, Hu Y, Bax R (2002) The future challenges facing the development of new antimicrobial drugs. Nature Rev Drug Discovr 11: 895.

6. Tenover FC (2006) Mechanisms of antimicrobial resistance in bacteria. American J Infect Conf 34: S3-S10.

7. Vranakis I, Goniotakis I, Psaroulaki A, Sandalakis V, Tselentis Y, et al. (2104) Proteome studies of bacterial antibiotic resistance mechanisms. J Proteomics 97: 88-99.

8. Richardson LA (2017) Understanding and overcoming antibiotic resistance. PLoS Biol 15: e2003775.

9. Kahn SE (2003) The relative contributions of insulin resistance and beta-cell dysfunction to the pathophysiology of type 2 diabetes. Diabetologia 46: 03-19.

10. Godreuil S, Tazi L, Bañuls AL (2007) Pulmonary tuberculosis and *Mycobacterium Tuberculosis*: modern molecular epidemiology and perspectives. Encyclopaedia of Infectious Diseases: Modern Methodologies. Hoboken, NJ: John Wiley & Sons.

11. World Health Organization (2015) Implementing the end TB strategy: The essentials.

12. Cosma CL, Sherman DR, Ramakrishnan L (2003) The secret lives of the pathogenic mycobacteria. Ann Rev Microbiol 57: 641-676.

13. Prasad R (2005) MDR-TB: Current status. Ind J Tuberculosis 52: 121.

14. Telenti A (1997) Genetics of drug resistance in tuberculosis. Clin Chest Med 18: 55-64.

15. Mehta B, Siddiquie A, Kaushik R, Bisht R, Sharma N (2015) Amplification of rpob, kat g and mab a (fab g1)-inh a promotor DNA sequences by PCR in multiple drug resistance tuberculosis. Int J Life Sci Sci Res 1: 15-18.

16. Sharma N, Sachan SK, Bushan I, Rai R, Shukla A, et al. (2017) Assessment of extensively drug resistant tuberculosis by studying the drug sensitivity pattern in north Indian region. J Microbiol Biotechnol Res 4: 31-33.

17. Xu J, Tozawa Y, Lai C, Hayashi H, Ochi K (2002) A Rifampicin resistance mutation in the *rpoB* gene confers ppGpp-independent antibiotic production in Streptomyces coelicolor A3 (2). Molecular Genetics and Genomics 268: 179-189.

18. Narotam S, Veena S, Raj SP, Kushwaha RS, Shivani S (2012) Conventional PCR usage for the detection of Mycobacterium Tuberculosis complex in Cerebrospinal Fluid by MPB64-Target PCR. Int J Drug Dev Res 4: 206-210.